The echinocandins (Q36742397)

16 August 2017

1 reference

title

The echinocandins (English)

1 reference

16 August 2017

1 reference

ChEBI release 2020-05-28

Diane Cappelletty

1

1 reference

16 August 2017

Kasi Eiselstein-McKitrick

series ordinal

2

1 reference

16 August 2017

language of work or name

English

0 references

publication date

1 March 2007

1 reference

16 August 2017

1 reference

16 August 2017

volume

27

1 reference

16 August 2017

issue

3

1 reference

16 August 2017

page(s)

369-388

1 reference

Changing patterns and trends in systemic fungal infections

16 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1592/PHCO.27.3.369

Multifocal Candida species colonization as a trigger for early antifungal therapy in critically ill patients: what about other risk factors for fungal infection?

21 January 2018

1 reference

https://api.crossref.org/works/10.1592/PHCO.27.3.369

Nosocomial bloodstream infections in United States hospitals: a three-year analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592/PHCO.27.3.369

Current trends in the epidemiology of nosocomial bloodstream infections in patients with hematological malignancies and solid neoplasms in hospitals in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1592/PHCO.27.3.369

Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study

21 January 2018

1 reference

https://api.crossref.org/works/10.1592/PHCO.27.3.369

The global epidemiology of invasive Candida infections--is the tide turning?

21 January 2018

1 reference

https://api.crossref.org/works/10.1592/PHCO.27.3.369

In-vitro activity of nikkomycin Z alone and in combination with polyenes, triazoles or echinocandins against Aspergillus fumigatus

21 January 2018

1 reference

https://api.crossref.org/works/10.1592/PHCO.27.3.369

Influences of methodological variables on susceptibility testing of caspofungin against Candida species and Aspergillus fumigatus

21 January 2018

1 reference

https://api.crossref.org/works/10.1592/PHCO.27.3.369

The antifungal echinocandin caspofungin acetate kills growing cells of Aspergillus fumigatus in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1592/PHCO.27.3.369

Pharmacokinetic and pharmacodynamic modeling of anidulafungin (LY303366): reappraisal of its efficacy in neutropenic animal models of opportunistic mycoses using optimal plasma sampling

21 January 2018

1 reference

https://api.crossref.org/works/10.1592/PHCO.27.3.369

Antifungal efficacy of caspofungin (MK-0991) in experimental pulmonary aspergillosis in persistently neutropenic rabbits: pharmacokinetics, drug disposition, and relationship to galactomannan antigenemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1592/PHCO.27.3.369

Comparative antifungal activities and plasma pharmacokinetics of micafungin (FK463) against disseminated candidiasis and invasive pulmonary aspergillosis in persistently neutropenic rabbits

21 January 2018

1 reference

https://api.crossref.org/works/10.1592/PHCO.27.3.369

Effects of caspofungin (MK-0991) and anidulafungin (LY303366) on phagocytosis, oxidative burst and killing of Candida albicans by human phagocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1592/PHCO.27.3.369

Micafungin enhances neutrophil fungicidal functions against Candida pseudohyphae

21 January 2018

1 reference

https://api.crossref.org/works/10.1592/PHCO.27.3.369

In vitro activity of micafungin (FK-463) against Candida spp.: microdilution, time-kill, and postantifungal-effect studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1592/PHCO.27.3.369

Pharmacodynamics of caspofungin in a murine model of systemic candidiasis: importance of persistence of caspofungin in tissues to understanding drug activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1592/PHCO.27.3.369

Pharmacodynamics of caspofungin in a murine model of invasive pulmonary aspergillosis: evidence of concentration-dependent activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1592/PHCO.27.3.369

In vitro pharmacodynamic properties of three antifungal agents against preformed Candida albicans biofilms determined by time-kill studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592/PHCO.27.3.369

Cilofungin (LY121019), an antifungal agent with specific activity against Candida albicans and Candida tropicalis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592/PHCO.27.3.369

Paradoxical effect of caspofungin: reduced activity against Candida albicans at high drug concentrations

21 January 2018

1 reference

https://api.crossref.org/works/10.1592/PHCO.27.3.369

Postantifungal effects of echinocandin, azole, and polyene antifungal agents against Candida albicans and Cryptococcus neoformans

21 January 2018

1 reference

https://api.crossref.org/works/10.1592/PHCO.27.3.369

A comparative study of the post-antifungal effect (PAFE) of amphotericin B, triazoles and echinocandins on Aspergillus fumigatus and Candida albicans

21 January 2018

1 reference

https://api.crossref.org/works/10.1592/PHCO.27.3.369

Interlaboratory comparison of results of susceptibility testing with caspofungin against Candida and Aspergillus species

21 January 2018

1 reference

https://api.crossref.org/works/10.1592/PHCO.27.3.369

Further standardization of broth microdilution methodology for in vitro susceptibility testing of caspofungin against Candida species by use of an international collection of more than 3,000 clinical isolates.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592/PHCO.27.3.369

In vitro susceptibility testing methods for caspofungin against Aspergillus and Fusarium isolates

21 January 2018

1 reference

https://api.crossref.org/works/10.1592/PHCO.27.3.369

In vitro activity of anidulafungin against selected clinically important mold isolates

21 January 2018

1 reference

https://api.crossref.org/works/10.1592/PHCO.27.3.369

In Vitro Activity of Two Echinocandin Derivatives, LY303366 and MK-0991 (L-743,792), Against Clinical Isolates of Aspergillus, Fusarium, Rhizopus, and Other Filamentous Fungi

21 January 2018

1 reference

https://api.crossref.org/works/10.1592/PHCO.27.3.369

In vitro activity of voriconazole, itraconazole, caspofungin, anidulafungin (VER002, LY303366) and amphotericin B against aspergillus spp.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592/PHCO.27.3.369

Method for measuring postantifungal effect in Aspergillus species

21 January 2018

1 reference

https://api.crossref.org/works/10.1592/PHCO.27.3.369

Antifungal susceptibility survey of 2,000 bloodstream Candida isolates in the United States.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592/PHCO.27.3.369

In vitro activities of anidulafungin against more than 2,500 clinical isolates of Candida spp., including 315 isolates resistant to fluconazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1592/PHCO.27.3.369

In vitro activities of caspofungin compared with those of fluconazole and itraconazole against 3,959 clinical isolates of Candida spp., including 157 fluconazole-resistant isolates.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592/PHCO.27.3.369

In vitro susceptibilities of bloodstream isolates of Candida species to six antifungal agents: results from a population-based active surveillance programme, Barcelona, Spain, 2002-2003.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592/PHCO.27.3.369

Activities of micafungin against 315 invasive clinical isolates of fluconazole-resistant Candida spp.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592/PHCO.27.3.369

In vitro activity of three new triazoles and one echinocandin against Candida bloodstream isolates from cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1592/PHCO.27.3.369

Comparison of the Antifungal Susceptibility Testing Subcommittee of the European Committee on Antibiotic Susceptibility Testing proposed standard and the E-test with the NCCLS broth microdilution method for voriconazole and caspofungin susceptibilit

21 January 2018

1 reference

https://api.crossref.org/works/10.1592/PHCO.27.3.369

Comparison of two methods and three end points in determination of in vitro activity of micafungin against Aspergillus spp.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592/PHCO.27.3.369

Activities of caspofungin, itraconazole, posaconazole, ravuconazole, voriconazole, and amphotericin B against 448 recent clinical isolates of filamentous fungi

21 January 2018

1 reference

https://api.crossref.org/works/10.1592/PHCO.27.3.369

Synergy, pharmacodynamics, and time-sequenced ultrastructural changes of the interaction between nikkomycin Z and the echinocandin FK463 against Aspergillus fumigatus

21 January 2018

1 reference

https://api.crossref.org/works/10.1592/PHCO.27.3.369

Combined activity in vitro of caspofungin, amphotericin B, and azole agents against itraconazole-resistant clinical isolates of Aspergillus fumigatus

21 January 2018

1 reference

https://api.crossref.org/works/10.1592/PHCO.27.3.369

In vitro synergy testing of anidulafungin with itraconazole, voriconazole, and amphotericin B against Aspergillus spp. and Fusarium spp.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592/PHCO.27.3.369

In vitro activity of caspofungin combined with sulfamethoxazole against clinical isolates of Aspergillus spp.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592/PHCO.27.3.369

Cryptococcus neoformans resistance to echinocandins: (1,3)beta-glucan synthase activity is sensitive to echinocandins

21 January 2018

1 reference

https://api.crossref.org/works/10.1592/PHCO.27.3.369

In vitro interactions of micafungin with other antifungal drugs against clinical isolates of four species of Cryptococcus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592/PHCO.27.3.369

In vitro synergistic interaction between amphotericin B and micafungin against Scedosporium spp.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592/PHCO.27.3.369

In vitro susceptibility of 15 strains of zygomycetes to nine antifungal agents as determined by the NCCLS M38-A microdilution method

21 January 2018

1 reference

https://api.crossref.org/works/10.1592/PHCO.27.3.369

In vitro antifungal activity of Micafungin (FK463) against dimorphic fungi: comparison of yeast-like and mycelial forms

21 January 2018

1 reference

https://api.crossref.org/works/10.1592/PHCO.27.3.369

In vitro interaction of micafungin with conventional and new antifungals against clinical isolates of Trichosporon, Sporobolomyces and Rhodotorula

21 January 2018

1 reference

https://api.crossref.org/works/10.1592/PHCO.27.3.369

The Candida albicans Cdr2p ATP-binding cassette (ABC) transporter confers resistance to caspofungin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592/PHCO.27.3.369

Overexpression of Candida albicans CDR1, CDR2, or MDR1 does not produce significant changes in echinocandin susceptibility

21 January 2018

1 reference

https://api.crossref.org/works/10.1592/PHCO.27.3.369

Specific substitutions in the echinocandin target Fks1p account for reduced susceptibility of rare laboratory and clinical Candida sp. isolates

21 January 2018

1 reference

https://api.crossref.org/works/10.1592/PHCO.27.3.369

Assessing resistance to the echinocandin antifungal drug caspofungin in Candida albicans by profiling mutations in FKS1

21 January 2018

1 reference

https://api.crossref.org/works/10.1592/PHCO.27.3.369

Multiechinocandin- and multiazole-resistant Candida parapsilosis isolates serially obtained during therapy for prosthetic valve endocarditis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592/PHCO.27.3.369

Progressive esophagitis caused by Candida albicans with reduced susceptibility to caspofungin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592/PHCO.27.3.369

Caspofungin resistance in Candida albicans: correlating clinical outcome with laboratory susceptibility testing of three isogenic isolates serially obtained from a patient with progressive Candida esophagitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592/PHCO.27.3.369

Progressive loss of echinocandin activity following prolonged use for treatment of Candida albicans oesophagitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592/PHCO.27.3.369

Amphotericin B and caspofungin resistance in Candida glabrata isolates recovered from a critically ill patient

21 January 2018

1 reference

https://api.crossref.org/works/10.1592/PHCO.27.3.369

Emergence of a Candida krusei isolate with reduced susceptibility to caspofungin during therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1592/PHCO.27.3.369

Population pharmacokinetic analysis of anidulafungin, an echinocandin antifungal

21 January 2018

1 reference

https://api.crossref.org/works/10.1592/PHCO.27.3.369

Pharmacokinetic and maximum tolerated dose study of micafungin in combination with fluconazole versus fluconazole alone for prophylaxis of fungal infections in adult patients undergoing a bone marrow or peripheral stem cell transplant

21 January 2018

1 reference

https://api.crossref.org/works/10.1592/PHCO.27.3.369

Single- and multiple-dose pharmacokinetics of caspofungin in healthy men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592/PHCO.27.3.369

Pharmacokinetics/pharmacodynamics of echinocandins

21 January 2018

1 reference

https://api.crossref.org/works/10.1592/PHCO.27.3.369

Assessment of the safety and pharmacokinetics of anidulafungin when administered with cyclosporine

21 January 2018

1 reference

https://api.crossref.org/works/10.1592/PHCO.27.3.369

Pharmacokinetics, safety, and tolerability of caspofungin in children and adolescents

21 January 2018

1 reference

https://api.crossref.org/works/10.1592/PHCO.27.3.369

Safety, tolerability, and pharmacokinetics of Micafungin (FK463) in febrile neutropenic pediatric patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1592/PHCO.27.3.369

Safety and pharmacokinetics of intravenous anidulafungin in children with neutropenia at high risk for invasive fungal infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1592/PHCO.27.3.369

Pharmacokinetics of micafungin in healthy volunteers, volunteers with moderate liver disease, and volunteers with renal dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1592/PHCO.27.3.369

Comparison of caspofungin and amphotericin B for invasive candidiasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592/PHCO.27.3.369

International, open-label, noncomparative, clinical trial of micafungin alone and in combination for treatment of newly diagnosed and refractory candidemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592/PHCO.27.3.369

Phase 2, randomized, dose-ranging study evaluating the safety and efficacy of anidulafungin in invasive candidiasis and candidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1592/PHCO.27.3.369

Randomized, double-blind, multicenter study of caspofungin versus amphotericin B for treatment of oropharyngeal and esophageal candidiases

21 January 2018

1 reference

https://api.crossref.org/works/10.1592/PHCO.27.3.369

A randomized double-blind study of caspofungin versus amphotericin for the treatment of candidal esophagitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592/PHCO.27.3.369

A randomized double-blind study of caspofungin versus fluconazole for the treatment of esophageal candidiasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592/PHCO.27.3.369

Successful treatment of oesophageal candidiasis by micafungin: a novel systemic antifungal agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1592/PHCO.27.3.369

A randomized, double-blind, parallel-group, dose-response study of micafungin compared with fluconazole for the treatment of esophageal candidiasis in HIV-positive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1592/PHCO.27.3.369

A randomized, double blind, comparative trial of micafungin (FK463) vs. fluconazole for the treatment of oesophageal candidiasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592/PHCO.27.3.369

A randomized, double-blind trial of anidulafungin versus fluconazole for the treatment of esophageal candidiasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592/PHCO.27.3.369

Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1592/PHCO.27.3.369

Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1592/PHCO.27.3.369

Salvage therapy with caspofungin for invasive aspergillosis: results from the caspofungin compassionate use study

21 January 2018

1 reference

https://api.crossref.org/works/10.1592/PHCO.27.3.369

Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1592/PHCO.27.3.369

Micafungin (FK463), alone or in combination with other systemic antifungal agents, for the treatment of acute invasive aspergillosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592/PHCO.27.3.369

A multicenter, open-label clinical study of micafungin (FK463) in the treatment of deep-seated mycosis in Japan

21 January 2018

1 reference

https://api.crossref.org/works/10.1592/PHCO.27.3.369

Combination antifungal therapy for invasive aspergillosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592/PHCO.27.3.369

Potential for interactions between caspofungin and nelfinavir or rifampin

21 January 2018

1 reference

https://api.crossref.org/works/10.1592/PHCO.27.3.369

Retrospective study of the hepatic safety profile of patients concomitantly treated with caspofungin and cyclosporin A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592/PHCO.27.3.369

Safety of the concomitant use of caspofungin and cyclosporin A in patients with invasive fungal infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1592/PHCO.27.3.369

Safety and pharmacokinetics of coadministered voriconazole and anidulafungin

21 January 2018

1 reference

https://api.crossref.org/works/10.1592/PHCO.27.3.369

Concomitant tacrolimus and micafungin pharmacokinetics in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1592/PHCO.27.3.369

21 January 2018

Identifiers

DOI

10.1592/PHCO.27.3.369

1 reference

16 August 2017

1 reference